Correlation Between Organon and Design Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Organon and Design Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Organon and Design Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Organon Co and Design Therapeutics, you can compare the effects of market volatilities on Organon and Design Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Organon with a short position of Design Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Organon and Design Therapeutics.

Diversification Opportunities for Organon and Design Therapeutics

-0.55
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Organon and Design is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Organon Co and Design Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Design Therapeutics and Organon is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Organon Co are associated (or correlated) with Design Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Design Therapeutics has no effect on the direction of Organon i.e., Organon and Design Therapeutics go up and down completely randomly.

Pair Corralation between Organon and Design Therapeutics

Considering the 90-day investment horizon Organon Co is expected to under-perform the Design Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Organon Co is 2.66 times less risky than Design Therapeutics. The stock trades about -0.25 of its potential returns per unit of risk. The Design Therapeutics is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  567.00  in Design Therapeutics on August 23, 2024 and sell it today you would lose (19.00) from holding Design Therapeutics or give up 3.35% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy95.65%
ValuesDaily Returns

Organon Co  vs.  Design Therapeutics

 Performance 
       Timeline  
Organon 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Organon Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of sluggish performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Design Therapeutics 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Design Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Design Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Organon and Design Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Organon and Design Therapeutics

The main advantage of trading using opposite Organon and Design Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Organon position performs unexpectedly, Design Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will offset losses from the drop in Design Therapeutics' long position.
The idea behind Organon Co and Design Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.